Curis (CRIS) – FDA
-
Curis (CRIS) Announces Initial Combination Study Data from its TakeAim Lymphoma Study
-
Curis (CRIS) Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to CRIS Stock Lookup